

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : C12Q 1/68, C12P 19/34		A1	(11) International Publication Number: WO 94/17210
			(43) International Publication Date: 4 August 1994 (04.08.94)
(21) International Application Number: PCT/US94/00748			(81) Designated States: AU, BR, CA, CZ, FI, JP, KR, NO, RU, SK, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date: 25 January 1994 (25.01.94)			
(30) Priority Data: 08/010,433 27 January 1993 (27.01.93) US 08/168,621 16 December 1993 (16.12.93) US			
(71) Applicant: ONCOR, INC. [US/US]; 209 Perry Parkway, Gaithersburg, MD 20877 (US).			
(72) Inventors: BHATNAGAR, Satish, K.; 21 Norwich Court, Gaithersburg, MD 20878 (US). GEORGE, Albert, L., Jr.; 12208 McDonald Chapel Drive, Gaithersburg, MD 20878 (US).			
(74) Agent: KARTA, Glenn, E.; Oncor, Inc., 209 Perry Parkway, Gaithersburg, MD 20877 (US).			Published With international search report.

(54) Title: AMPLIFICATION OF NUCLEIC ACID SEQUENCES

(57) Abstract

A process for amplifying nucleic acid sequences from a DNA or RNA template which may be purified, or may exist in a mixture of nucleic acids. The resulting nucleic acid sequences may be exact copies of the template, or may be modified. The process has advantages over prior art amplification processes in that it increases the fidelity of copying a specific nucleic acid sequence, and it allows one to more efficiently detect a particular point mutation in a single assay (see figure 1).



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## AMPLIFICATION OF NUCLEIC ACID SEQUENCES

### Cross Reference to Related Application

- 5        This application is a continuation-in-part of application Serial No. 08/010,433 filed January 27, 1993.

### BACKGROUND OF THE INVENTION

#### 10    1. Field of the Invention

- The present invention relates to a process for amplifying nucleic acid sequences. More specifically, it relates to an improved process for producing nucleic acid sequences from a DNA or RNA template which may be purified, or may exist in a mixture of nucleic acids. The resulting nucleic acid sequences may be exact copies of the template, or may be modified.

#### 20    2. Description of Related Art

- In the past, methods have been employed for amplifying nucleic acid sequences wherein both strands of the nucleic acid sequence to be amplified are synthesized by the same method. Such methods are prone to limitations due to the nature of the enzymes utilized in these processes.
- 25        In U.S. Patents No. 4,683,195 and 4,683,202, DNA or RNA is amplified by the polymerase chain reaction (PCR). These patents are incorporated herein by reference in their entirety. This method involves the hybridization of an oligonucleotide primer to the 5' end of each complementary strand of the double-stranded target nucleic acid. The primers are extended from the 3' end in a 5' → 3' direction by a DNA polymerase which incorporates free nucleotides into a nucleic acid sequence complementary to each strand of the target nucleic acid. After dissociation of the extension products from the target nucleic acid strands, the extension products become target sequences for the next cycle. In order to obtain satisfactory amounts of the amplified DNA, repeated cycles must be carried out,

between which cycles, the complementary DNA strands must be denatured under elevated temperatures.

Traditional polymerases used in this process, such as *E. coli* DNA polymerase I have the limitation of being  
5 inactivated at temperatures necessary for the denaturation of the complementary strands. Thus, between each cycle of synthesis by such polymerases and after the heat denaturation step, a fresh aliquot of enzyme must be added to the reaction mixture so that extension of the primer and  
10 synthesis of the complementary strand may occur in the following cycle. This additional step increases the time required for amplification and decreases the ease of amplification which requires multiple steps.

In recent years, thermostable DNA polymerases have been  
15 discovered and isolated from thermophilic organisms such as *Thermus aquaticus*. Such thermostable polymerases make it possible to add enzyme at the beginning of a series of synthesis and denaturation steps, without the need to add a new aliquot of enzyme after each denaturation step.

20 A potential problem associated with PCR is the hybridization of a primer sequence to regions of the DNA molecule not intended to be amplified. Generally these undesired hybridizations occur because the target sample contains, in addition to the target sequence itself, other  
25 sequences with some complementarity to the primer sequences. If the 3' terminal nucleotides of the primer molecule are successfully hybridized to a sequence other than the target sequence, it is possible that primer extension may be successfully initiated by the polymerase  
30 enzyme, leading to the generation of an extension product different from the desired target sequence. Under some circumstances, this extension product will undergo exponential amplification, and be erroneously thought to be the desired target sequence.

35 A method of detecting a specific nucleic acid sequence present in low copy in a mixture of nucleic acids, called

ligase chain reaction (LCR), has also been described. European patent application 0 320 308 describes this method and is incorporated herein by reference in its entirety. Target nucleic acid in a sample is annealed to probes  
5 containing contiguous sequences. Upon hybridization, the probes are ligated to form detectable fused probes complementary to the original target nucleic acid. The fused probes are disassociated from the nucleic acid and serve as a template for further hybridizations and fusions  
10 of the probes, thus amplifying geometrically the nucleic acid to be detected. The method does not use DNA polymerase.

LCR has disadvantages due to the need for at least four separate oligonucleotide probes for amplification. It also  
15 requires that the entire sequence of the target nucleic acid be known. Further, background signal can be caused by target independent ligation of the probes. Since the third probe hybridizes to the first probe and the fourth probe hybridizes to the second probe, the probes, when  
20 added in excess, can easily form duplexes among themselves which can be ligated independently of the target nucleic acid.

European Application No. 0 439 182 which is incorporated herein in its entirety by reference discloses a method of  
25 improving LCR amplification by providing probes/primers which hybridize to the target nucleic acid wherein one end is modified such that ligation cannot occur until the modified end is corrected. One such modification is the placement of a small gap between the probes preventing  
30 ligation of the probes. The gap sequence of the target nucleic acid must be selected such that the DNA sequence is comprised of three or less different nucleotides from the four possible nucleotides. The fourth nucleotide must be the first base complementary to the 5' end of the adjacent  
35 probe. The gap is then filled using a DNA polymerase or reverse transcriptase to extend one or more of the probes

in a 5' to 3' direction in a target dependent manner to render the probes ligatable. The reaction mixture omits the fourth deoxynucleoside triphosphate complementary to the base at the 5' end of the adjacent probe. Because this method requires that the gap chosen in the target nucleic acid only contains bases which are complementary to a maximum of three of the deoxynucleoside triphosphates, the method limits the location of the gap on the target nucleic acid and also limits the size of the gap. Further, the method requires four primers. The application also discloses a method of PCR amplification wherein one end of the primer is modified such that the primer is not extendable by a polymerase enzyme. When this modification is removed in a template dependent manner, the primer can be extended. However, this type of PCR requires an additional step of removal of the modification before extension can occur.

In view of the foregoing disadvantages attendant with prior art methods of amplifying nucleic acid sequences, it should be apparent that there exists a need in the art for a method in which the fidelity of amplified sequences can be increased, which allows for the detection of a particular nucleic acid strand, and which allows one to efficiently examine multiple alleles in a single series of amplification steps.

#### SUMMARY OF THE INVENTION

The present invention is based on the discovery that certain aspects of LCR and PCR can be used in combination to detect and amplify a target nucleic acid sequence with increased fidelity. Accordingly, in one of its process aspects, the present invention relates to a process for amplifying enzymatically a target nucleic acid sequence contained in a nucleic acid or a mixture of nucleic acids, comprising the steps of:

- a. selecting the target nucleic acid sequence;

-5-

- b. providing primers, said primers comprising a first primer which is substantially complementary to a first segment at a first end of the target nucleic acid sequence and a second primer which is substantially complementary to a second segment at a second end of the target nucleic acid sequence and whose 3' end is adjacent to the 5' end of the first primer and a third primer which is similar to the first end of the target nucleic acid sequence and which is substantially complementary to at least a portion of said first primer;
- c. providing at least four different nucleotide bases;
- d. hybridizing said first and second primers to the target nucleic acid sequence in a target dependent manner to form a primer-target complex;
- e. ligating under conditions such that the adjacent 5' end of the first primer and the 3' end of the second primer will ligate to form a fused amplification product substantially complementary to said target nucleic acid sequence;
- f. dissociating said fused amplification product from said target nucleic acid sequence;
- g. hybridizing said third primer to said fused amplification product;
- h. extending said third primer in the presence of the nucleotide bases under conditions such that an extended amplification product is formed substantially complementary to said fused amplification product;
- i. optionally dissociating the extended amplification product from the fused amplification product.

In another of its process aspects, the present invention relates to a process for detecting enzymatically a point mutation or allele of a target nucleic acid sequence contained in a nucleic acid or a mixture of nucleic acids using the method disclosed above. One of said primers is comprised of a number of similar oligonucleotide sequences,

one of which is exactly complementary to the possible allele or point mutation and each of which oligonucleotides is labeled with a different label. The allele is determined by detecting which labeled oligonucleotide is  
5 contained within the resulting amplification products.

In a third aspect, the present invention relates to a process for amplifying enzymatically a target nucleic acid sequence contained in a nucleic acid or a mixture of nucleic acids comprising the steps of:

- 10 a. selecting the target nucleic acid sequence;
- b. providing primers, said primers comprising a first primer which is substantially complementary to a first segment at a first end of the target nucleic acid sequence and a second primer which is substantially  
15 complementary to a second segment at a second end of the target nucleic acid sequence said second segment being spaced from said first segment and a third primer which is similar to the first end of the target nucleic acid sequence and which is substantially complementary to a  
20 portion of said first primer;
- c. providing at least four different nucleotide bases;
- d. hybridizing said first and second primers to the target nucleic acid sequence in a target dependent,  
25 manner to form a primer-target complex;
- e. extending the 3' end of the second primer in the presence of the nucleotide bases under conditions such that an extended second primer is formed wherein the 3' end of the extended second primer terminates at a base adjacent  
30 to the 5' end of the first primer;
- f. ligating the ends of the first and second extended primers under conditions such that said first and said extended second primers will form a fused amplification product substantially complementary to said  
35 target nucleic acid sequence;
- g. dissociating said fused amplification product



-7-

from said target nucleic acid sequence;

h. hybridizing said third primer to said fused amplification product;

5 i. extending said third primer in the presence of the nucleotide bases under conditions such that an extended amplification product is formed substantially complementary to said fused amplification product; and

j. optionally dissociating the extended amplification product from the fused amplification product.

10 In one of its product aspects, the present invention relates to a kit for amplifying a target nucleic acid sequence contained in a nucleic acid or a mixture of nucleic acids comprising: first, second, and third primers and optionally a fourth primer; a ligating enzyme; a  
15 polymerizing enzyme; and at least four nucleotides.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts one embodiment of the method of DNA amplification/detection as set forth herein.

20 Figure 2 is a printout from a Phosphor Imager of a scanned acrylamide gel. The arrow indicates the resulting higher molecular weight amplification products.

Figure 3 depicts another embodiment of the method of DNA amplification/detection as set forth herein.

25 Figure 4 shows a portion of the sequence of the multidrug resistance gene (MDR-1) (SEQ ID NO:1).

Figures 5-11 are printouts from a Phosphor Imager of a scanned acrylamide gel which show amplification achieved with various embodiments of the present invention.

30 Figure 12 depicts another embodiment of the method of DNA amplification/detection as set forth herein.

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

35 Prior to discussing this invention in detail, the following terms will first be defined:

The "target nucleic acid" or "target nucleic acid

sequence" suitable for use in the present invention may be taken from prokaryotic or eukaryotic DNA or RNA, including from plants, animals, insects, microorganisms; etc., and it may be isolated or present in samples which contain nucleic acid sequences in addition to the target nucleic acid sequence to be amplified. The target nucleic acid sequence may be located on a nucleic acid strand which is longer than the target nucleic acid sequence. In this case, the ends of the target nucleic acid sequence are the boundaries with the unselected nucleic acid sequence and the target nucleic acid sequence. The target nucleic acid sample may be obtained synthetically, or can be isolated from any organism by methods well known in the art. Particularly useful sources of nucleic acid are derived from tissues or blood samples of an organism, nucleic acids which are present in self-replicating vectors, and nucleic acids derived from viruses and pathogenic organisms such as bacteria and fungi. Also particularly useful for the present invention are target nucleic acid sequences which are related to disease states, such as those caused by chromosomal rearrangement, insertions, deletions, translocations and other mutations, those caused by oncogenes, and those associated with cancer.

The term "selected" means that a target nucleic acid sequence having the desired characteristics is located and probes are constructed around appropriate segments of the target sequence.

The term "probe" or "primer" has the same meaning herein, namely, an oligonucleotide fragment which is single stranded. The term "oligonucleotide" means DNA or RNA.

A probe or primer is "substantially complementary" to the target nucleic acid sequence if it hybridizes to the sequence under renaturation conditions so as to allow target dependent ligation or extension. Renaturation depends on specific base pairing between A-X (where X is T or U) and G-C bases to form a double stranded duplex

structure. Therefore, the primer sequence need not reflect the exact sequence of the target nucleic acid sequence. However, if an exact copy of the target nucleic acid is desired, the primer should reflect the exact sequence.

5 Typically, a "substantially complementary" primer will contain at least 70% or more bases which are complementary to the target nucleic segment. More preferably 80% of the bases are complementary and most preferably 90% of the bases are complementary. Generally, the primer must  
10 hybridize to the target nucleic acid sequence at the end to be ligated or extended to allow target dependent ligation or extension.

The primers may be RNA or DNA, and may contain modified nitrogenous bases which are analogs of the normally  
15 incorporated bases, or which have been modified by attaching labels or linker arms suitable for attaching labels. Inosine may be used at positions where the target sequence is not known, or where it may be degenerate. The oligonucleotides must be sufficiently long to allow  
20 hybridization of the primer to the target nucleic acid and to allow amplification to proceed. They are preferably 15 to 50 nucleotides long, more preferably 20 to 40 nucleotides long, and most preferably 25 to 35 nucleotides long. The nucleotide sequence, content and length will  
25 vary depending on the sequence to be amplified.

It is contemplated that a primer may comprise one or more oligonucleotides which comprise substantially complementary sequences to the target nucleic acid sequence. Thus, under less stringent conditions, each of  
30 the oligonucleotides would hybridize to the same segment of the target nucleic acid. However, under increasingly stringent hybridization conditions, only that oligonucleotide sequence which is most complementary to the target nucleic acid sequence will hybridize. The  
35 stringency of conditions is generally known to those in the art to be dependant on temperature, solvent and other

parameters. Perhaps the most easily controlled of these parameters is temperature and since the conditions here are similar to those of PCR, one skilled in the art could determine the appropriate conditions required to achieve the level of stringency desired.

5 Oligonucleotide primers or oligonucleotide probes suitable for use in the present invention may be derived by any method known in the art, including chemical synthesis, or by cleavage of a larger nucleic acid using non-specific  
10 nucleic acid-cleaving chemicals or enzymes, or by using site-specific restriction endonucleases.

The primers may be prepared using the  $\beta$ -cyanoethyl-phosphoramidite method or other methods known in the art. A preferable method for synthesizing oligonucleotide  
15 primers is conducted using an automated DNA synthesizer by methods known in the art. Once the desired oligonucleotide primer is synthesized, it is cleaved from the solid support on which it was synthesized, and treated, by methods known in the art, to remove any protecting groups present. The  
20 oligonucleotide primer may then be purified by any method known in the art, including extraction and gel purification. The concentration and purity of the oligonucleotide primer may be examined on an acrylamide gel, or by measuring the optical densities at 260 and 280  
25 nm in a spectrophotometer.

In order for the ligase to ligate the oligonucleotide primers, the primers used in the present invention are preferably phosphorylated at their 5' ends. This may be achieved by any method known in the art, but is preferably  
30 conducted with the enzyme T4 polynucleotide kinase. The oligonucleotides can be phosphorylated in the presence of unlabeled or labeled ATP. In order to monitor the amplification process, labeled ATP may be used to phosphorylate the primers. Particularly preferable is [ $\gamma$ -  
35  $^{32}\text{P}$ ] ATP.

The oligonucleotide primers may alternatively be labeled with any detectable marker known in the art, including other radioactive nuclides such as  $^{35}\text{S}$  or  $^3\text{H}$  and the like, fluorescent markers such as fluorescein, rhodamine, Texas red, Lucifer yellow, AMCA blue and the like, or with enzymatic markers which may produce detectable signals when a particular chemical reaction is conducted, such as alkaline phosphatase or horseradish peroxidase. Such enzymatic markers are preferably heat stable, so as to survive the denaturation steps of the amplification process. Primers may be indirectly labeled by incorporating a nucleotide covalently linked to a hapten or other molecule such as biotin to which a labeled avidin molecule may be bound, or digoxigenin, to which a labeled anti-digoxigenin antibody may be bound.

Primers may be labeled during chemical synthesis or the label may be attached after synthesis by methods known in the art. The method of labeling and the type of label is not critical to this invention.

It is contemplated that the probes or primers may be modified. For example the hydrolysis of a primer by 5' to 3' exonuclease associated with polymerase may be prevented by placing a phosphorothioate group between the last nucleotides of the 5' end of the primer. The extension of a primer by polymerase can be blocked by placing a dideoxynucleotide, an amino group, a cordycepin, or a phosphate group at the 3' end. Alternatively, the extension of a primer may be blocked by placing an arabinosyl nucleotide at the 3' end of the primer which blocks extension by polymerase but allows ligation of the primer to another primer.

The term "the four different nucleotide bases" shall refer to deoxythymidine triphosphate (dTTP); deoxyadenosine triphosphate (dATP); deoxyguanosine triphosphate (dGTP); and deoxycytidine triphosphate (dCTP), when the context is DNA, but shall refer to uridine triphosphate (UTP);

-12-

adenosine triphosphate (ATP); guanosine triphosphate (GTP); and cytidine triphosphate (CTP) when the context is RNA. Alternatively, dUTP, dTTP, rITP or any other modified base may replace one of the four nucleotide bases or may be included along with the four nucleotide bases in the reaction mixture so as to be incorporated into the amplified strand. The amplification steps are conducted in the presence of at least the four deoxynucleoside triphosphates (dATP, dCTP, dGTP and dTTP) or a modified nucleoside triphosphate to produce a DNA strand, or in the presence of the four ribonucleoside triphosphates (ATP, CTP, GTP and UTP) or a modified nucleoside triphosphate to produce an RNA strand from extension of the oligonucleotide which acts as a primer.

Where the presence of a particular mutation or allele is to be detected by the methods of this invention, one of the oligonucleotide primers may comprise a set of oligonucleotide fragments, each differing in sequence and each labeled by a different method. That oligonucleotide fragment which is exactly complementary to the target DNA sequence will be detected by the presence of that label in the amplification products. In this case, each oligonucleotide fragment may be labeled as described above.

## Utility

### First Embodiment

In a first embodiment, the target nucleic acid is described as single stranded. However, this should be understood to include the case where the target is actually double stranded but is simply separated from its complementary strand prior to hybridization with probes/primers. Primers one and two, together, are substantially complementary to the target nucleic acid sequence and hybridize to adjacent regions of the target nucleic acid strand such that upon hybridization of the two

primers to the target nucleic acid strand the 5' end of the first primer is adjacent to the 3' end of the second primer. The 3' end of the first primer is substantially complementary to the 5' end of the target nucleic acid sequence and the 5' end of the second primer is substantially complementary to the 3' end of the target nucleic acid sequence. The 5' end of the first primer is ligated to the 3' end of the second primer using ligase to create a fused amplification product in a double stranded complex. The fused primer is dissociated from the target nucleic acid.

The third primer is substantially complementary to all or at least a portion of the first primer and is similar to the 5' end of the target nucleic acid. The third primer should be complementary to enough of the first primer so that specific hybridization is achieved under the conditions used. The third primer may be smaller than the first primer or it may be larger than the first primer and also be substantially complementary to a portion of the second primer. The third primer is hybridized to the fused amplification product and extended by polymerase in the presence of at least four different nucleotide bases to form an extended amplification product which is substantially complementary to the fused amplification product. This comprises the first cycle.

Subsequently the double stranded complexes are dissociated. The oligonucleotide primers (1 and 2) are hybridized to the target nucleic acid sequence and the extended amplification product from the first cycle. Primer 3 is hybridized to the fused amplification product. Extension and ligation occur as before and the process can be repeated.

It is contemplated that the 3' end of the second primer may be modified to block the extension of the second primer by polymerase while still allowing ligation of the 3' end of the second primer to the 5' end of the first primer.

Such modification may be, for example, the placement of an arabinosyl nucleotide at the 3' end of the second primer. Methods for the chemical synthesis of DNA oligomers containing cytosine arabinoside are known in the art (Beardsley, Nucl. Acid. Res. (1988) 16:9165-9176). Such a modification does not need to be removed prior to the ligation of the first and second primers.

Alternatively, it is also contemplated that the 5' end of the first primer can be modified to prevent the hydrolysis of the primer by a 5' to 3' exonuclease associated with a polymerase. Such a modification may be, for example, the placement of a phosphorothioate group between the last nucleotides of the 5' end of the first primer. Methods for the chemical synthesis of phosphorothioate containing primers is known in the art (Ott and Eckstein, Biochemistry, (1987) 26:8237-8241). Such a modification does not need to be removed prior to ligation of the first and second primers.

It is further contemplated that extension of the first primer can be prevented without affecting the ligation of this primer by modifying the 3' end of the primer with a dideoxynucleotide or a phosphate group. The method for producing this modification is known in the art (Markiewicz and Wyrzykiewicz Nucl. Acid. Res. (1989) 17:7149-7158).

It has been found that the process can be conducted sequentially without isolation or purification of the products or removal of the excess reagents. Accordingly, this will allow the entire process to be conducted in a single reaction medium (e.g. a test tube).

It is understood that the single strand variation is a more specialized version of the double strand variation. If the target nucleic acid is double stranded some of the third primers will hybridize to the second complementary strand and the first and second primers will hybridize to the first strand. The extension and ligation from the first strand will proceed as described above. Some of the



third primers will also be extended in a target specific manner complementary to the second strand. After dissociation of the extended third primer and the second strand, at least some of the first and second primers will  
5 hybridize to the extended third primer and at least some of the third primer will again hybridize to the second strand.

Where the target nucleic acid amplified by ligation of the first and second primers and extension of the third primer is to be detected, one or all of these primers may  
10 be labeled using a marker as described above to render the amplified target nucleic acid detectable or by conducting the extension of the third primer in the presence of a labeled base, or a base which is activated for labeling.

Alternatively, where the target nucleic acid is double  
15 stranded, both amplified strands may be labeled with different detectable markers: the first strand may be labeled by labeling the third primer with a particular marker; and the second strand may be labeled by labeling the first and/or second primer.

20 In the case where the presence of a particular point mutation or allele is to be detected, one primer comprising a mixture of oligonucleotides is added to the nucleic acid sample. Each oligonucleotide may be labeled with different, separately detectable markers, so that  
25 information regarding the presence of a particular mutation or allele may be obtained in a single step. The oligonucleotide which is exactly complementary to the target sequence will be included in the amplification product whereas the other oligonucleotides will not and its  
30 presence detected by determining which label is included in the product.

The amplification reaction is optimally conducted with an excess of primers at a ratio of oligonucleotide primers:target of approximately  $10^7$  to  $10^3:1$ , more  
35 preferably approximately  $10^4:1$ . It is contemplated that adjusting the molarity of the primers will maximize the

efficiency of the process.

The buffer used for amplification is preferably in a pH range of about 7.5-8.5, more preferably about 8-8.5, and most preferably about 8.0.

5

#### Second Embodiment

In a second embodiment, the target nucleic acid is described to be single stranded. However, this should be understood to include the case where the target is actually double stranded, but is simply separated from its complementary strand prior to hybridization with the probes/primers.

The target nucleic acid is hybridized to two primers. The first primer is substantially complementary to the 5' end of the target nucleic acid sequence and the second primer is substantially complementary to the 3' end of the target nucleic acid sequence. The primers (primers one and two) hybridize to regions of the target nucleic acid strand such that upon hybridization of the two primers to the target nucleic acid strand the 5' end of the first primer is spaced from the 3' end of the second primer. The size of the space or gap between the primers is determined by the ability of a polymerase or transcriptase to extend the second primer such that the newly added 3' end of the second primer is directly adjacent to the 5' end of the first primer. Preferably, but not necessarily, the size of the gap or space is sufficiently long such that at least four different nucleotides would be required by the polymerase or transcriptase in order to extend the second primer to "fill in" the gap.

The 3' end of the second primer is extended by polymerase or transcriptase in the presence of the four nucleotide bases. The 5' end of the first primer is then ligated to the new 3' end of the second extended primer to form a double-stranded complex comprising the target nucleic acid and an extended fused primer.

-17-

The double stranded complex is dissociated and a third primer is hybridized to the extended fused primer. The third primer is substantially complementary to all or a portion of the first primer and is similar to the 5' end of the target nucleic acid sequence. The 3' end of the third primer is extended by polymerase or transcriptase to form a double-stranded complex and complete the cycle. The double-stranded complex is dissociated and the cycle repeated until the target nucleic acid is amplified. It will be understood that when the target sequence is part of a double stranded nucleic acid as shown in Fig. 12, some of the third primers present will hybridize to the second strand complementary to the target sequence, and will be extended to form an amplification product.

It is contemplated that the process can be conducted sequentially without isolation or purification of the products or removal of the excess reagents. Accordingly, this will allow the entire process to be conducted in a single reaction medium (e.g. a test tube). Further, because the gap between the primers can be any size as discussed above, the method is not limited to a particular DNA sequence and extension of the third primer can proceed in the presence of four nucleotides.

It is understood that the single strand variation is a more specialized case of the double strand variation wherein there are four primers and the first and second primers are substantially complementary to the first strand of the target nucleic acid and the third and fourth primers are substantially complementary to the second strand of the target nucleic acid. The third primer is substantially complementary to at least a portion of the first primer and the fourth primer is substantially complementary to at least a portion of the second primer. The extension and ligation of the third and fourth primers occurs as described above for the first and second primers. It will be understood that at least some of the third and fourth

primers will hybridize to the extended fused primer (first and second primers). The third primer is then extended and ligation to the fourth primer occurs.

5 It is contemplated that the 5' end of the first primer (and the 5' end of the fourth primer, where the nucleic acid is double stranded) can be modified to prevent the hydrolysis of the primer by a 5' to 3' exonuclease associated with the polymerase. Such a modification may be, for example, the placement of a phosphorothioate group  
10 between the last nucleotides of the 5' end of the first or fourth primers. Methods for the chemical synthesis of phosphorothioate containing primers is known in the art (Ott and Eckstein, Biochemistry, (1987) 26:8237-8241). Such a modification does not need to be removed prior to  
15 ligation of the first and second primers.

In connection with the "gap filling" embodiments of the present invention, it will be appreciated that certain DNA polymerases possess a DNA polymerising associated strand displacement activity. It is preferable to reduce or  
20 eliminate that activity, as it could lead to displacement of the nonextended primer. For example, referring to Figure 3, unless this activity is reduced or eliminated, the extension of oligo 2 or oligo 3 could result in the displacement of oligo 1 or oligo 4, respectively.

25 Strand displacement activity is related to the processivity of the DNA polymerase. Processivity of DNA polymerase is defined as the number of nucleotide residues added per enzyme binding event. A DNA polymerase enzyme with a high degree of processivity will show a strong  
30 strand displacement activity. The processivity of the enzyme is affected by factors such as 1) salt concentration, 2) nucleotide concentration, and 3) divalent cations. We have found that:

1) Increasing the salt concentration during primer  
35 extension will lower the processivity, thereby decreasing the displacement of the companion oligo. This will promote

ligation to the extended product.

2) Decreasing the nucleotide concentration of the residue at the 5'-end of the oligo not being extended (oligos 1 and 4 in Figure 3) will cause the DNA polymerase to pause before incorporating the limiting nucleotide during primer extension. Pausing at the 5'-end of primer 1 extends the time for DNA ligase to seal the gap.

3) Placing a non-extendable arabinosyl derivative of the nucleotide at the 3'-end of the oligo being extended will prevent both the extension of primer 2 and the displacement of primer 1 by DNA polymerase. This helps in the "no gap" version whereby primer 1 and primer 2 are positioned adjacently.

It is further contemplated that extension of the first and fourth primers can be prevented without affecting the ligation of these primers by modifying the 3' end of the primers with a dideoxynucleotide or a phosphate group. This method of producing this modification is known in the art (Markiewicz and Wyrzykiewicz Nucl. Acid. Res. (1989) 17:7149-7158).

Where the target nucleic acid amplified is to be detected, one or all of these primers may be labeled as described above to render the amplified strand detectable. Alternatively the strand may be labeled by conducting the extension of the second or third primer in the presence of a labeled base, or a base which is activated for labeling.

In the case where one primer comprises a mixture of oligonucleotides to detect the presence of a particular sequence, each of the oligonucleotides may be labeled with different, separately detectable markers, so that information regarding each mutation may be obtained in a single step.

The amplification reaction is optimally conducted with an excess of primers at a ratio of oligonucleotide primers:target of approximately  $10^7$  to  $10^3:1$ , more preferably approximately  $10^4:1$ . It is contemplated that

adjustment of the molarity of the primers will maximize the efficiency of the process.

The buffer used for amplification is preferably in a pH range of about 7.5-8.5, more preferably about 8-8.5, and  
5 most preferably about 8.0.

If the target nucleic acid is double stranded, the strands should be separated so that they can be used individually. This separation can be accomplished by any suitable denaturation method including physical, chemical  
10 or enzymatic means, each of which are well known in the art.

In either of the above embodiments, the amplification reaction will involve a series of steps. The reaction may be either a two step process [i.e. 1) hybridization/extension/-  
15 ligation followed by 2) denaturation] or a three step process [1) hybridization; 2) extension/ligation and 3) denaturation). These steps may be carried out manually, but they are preferably conducted in an automated thermal cyclor.

20 Hybridization is generally conducted at a temperature of approximately 50-75°C for a period of 0.5-2 minutes, more preferably at 60-70°C for a period of 1-1.5 minutes, and most preferably at about 63-68°C for about 1 minute. The extension/ligation or the hybridization/extension/ligation  
25 steps are generally conducted at a temperature of approximately 60-80°C for a period of 0.5-5 minutes, more preferably at 68-78°C for a period of 2-4 minutes.

The conditions and reagents which make possible the preferred enzymatic ligation step are generally known to  
30 those of ordinary skill in the art and depend directly on the type of ligase used. The "ligating enzyme" may be any enzyme known in the art to ligate nucleic acid sequences, including T4 ligase, but it is preferably a ligase stable at temperatures of approximately 0-95°C, such as AMPLIGASE  
35 (Epicentre Technologies, Madison Wisconsin), Taq ligase (New England Biolabs, Beverly, Massachusetts) and Pfu

ligase (Stratagene, La Jolla, California). Absent a thermally stable ligase, the ligase must be added again each time the cycle is repeated. Approximately at least 5 units of ligating enzyme/picomole of oligonucleotide is used. One unit is defined as the amount required to catalyze the ligation of 50% of the cos sites in one microgram of BstE II digested bacteriophage  $\lambda$  DNA in a total volume of 50  $\mu$ l in fifteen minutes at 45°C.

The "polymerase" may be any enzyme capable of polymerizing an RNA or DNA strand, including E. coli DNA polymerase I, the Klenow fragment of E. coli DNA polymerase I, AmpliTaq DNA polymerase Stoffel fragment, T4 DNA polymerase, RNA polymerase or reverse transcriptase. In general, the primer is extended by the polymerase in a target dependent manner, for example, under conditions such that a nucleic acid strand is formed complementary to the nucleic acid sequence to which the primer is hybridized. Preferably, the polymerizing enzyme is stable at temperatures of approximately 0-95°C, such as Taq DNA polymerase (Perkin-Elmer Corporation, Norwalk, Connecticut). Absent a thermally stable polymerase, the polymerase must be added again each time the cycle is repeated. At least approximately 0.5 units of polymerizing enzyme (as defined by the manufacturer)/picomole of oligonucleotide is used.

Extension of a primer by polymerase or transcriptase proceeds in a 5' to 3' direction and requires the addition in adequate amounts of at least the four nucleotide bases in the reaction mixture.

After extension of the primers, it is necessary to separate the nucleic acid strands. The strand separation can be accomplished by any suitable denaturing method including well-known physical, chemical or enzymatic means. For example, one physical method of separating the strands of the nucleic acid involves heating the nucleic acid until

it is completely denatured. Typical heat denaturation is generally conducted at a temperature of approximately 85-110°C, more preferably at 90-100°C, and most preferably at about 92-96°C for a period of at least about 0.5 minutes. One skilled in the art would understand how to modify the temperatures and times so as to optimize the results obtained with different oligonucleotide primers. Alternatively, denaturation can be achieved by other methods known in the art. One such method is by the introduction of a nucleic acid-unwinding enzyme such as helicase.

The reaction is stopped by any method known in the art, such as with a buffer containing a high percentage of denaturant such as formamide, EDTA or by freezing. The products can then be analyzed by any method, but electrophoresis on a polyacrylamide gel is preferable. Preferably, the samples are boiled before loading on the gel to eliminate any secondary structures. The gel may then be dried and placed against autoradiographic film or phosphor screen when the oligonucleotides or amplified strands contain radioactive nuclides. The gel may also be blotted and probed with a probe specific to the region amplified.

The primer may be labeled with a detectable marker by any method known in the art. A preferred method for labeling primers is by end labeling. Primers may be labeled during chemical synthesis by substitution of the <sup>31</sup>P atoms in the phosphate groups with <sup>32</sup>P. The substituted nucleotide may be directly labeled or contain a linker arm for attaching a label, or may be attached to a hapten or other molecule to which a labeled binding molecule may bind (Boehringer Mannheim, Indianapolis, Indiana). Suitable direct labels include radioactive labels such as <sup>32</sup>P, <sup>3</sup>H, and <sup>35</sup>S and non-radioactive labels such as fluorescent markers, such as fluorescein, Texas Red, AMCA blue, lucifer yellow, rhodamine, and the like; cyanin dyes which are



detectable with visible light; enzymes and the like.

Fluorescent markers may alternatively be attached to nucleotides with activated linker arms. Primers may be indirectly labeled by the methods disclosed above, by incorporating a nucleotide covalently linked to a hapten or other molecule such as biotin or digoxigenin, and performing a sandwich hybridization with a labeled antibody directed to that hapten or other molecule, or in the case of biotin, with avidin conjugated to a detectable label. Antibodies and avidin may be conjugated with a fluorescent marker, or with an enzymatic marker such as alkaline phosphatase or horseradish peroxidase to render them detectable. Conjugated avidin and antibodies are commercially available from companies such as Vector Laboratories (Burlingame, California) and Boehringer Mannheim (Indianapolis, Indiana).

The enzyme can be detected through a colorimetric reaction by providing a substrate and/or a catalyst for the enzyme. In the presence of various catalysts, different colors are produced by the reaction, and these colors can be visualized to separately detect multiple probes. Any substrate and catalyst known in the art may be used. Preferred catalysts for alkaline phosphatase include 5-bromo-4-chloro-3-indolylphosphate (BCIP) and nitro blue tetrazolium (NBT). The preferred substrate for horseradish peroxidase is diaminobenzoate (DAB).

The following examples are presented in order to more fully illustrate the preferred embodiments of the invention. They should in no way be construed, however, as limiting the broad scope of the invention.

Abbreviations:

ATP	-	adenosine triphosphate
dATP	-	deoxyadenosine triphosphate
CTP	-	cytidine triphosphate
dCTP	-	deoxycytidine triphosphate
GTP	-	guanosine triphosphate

-24-

	dGTP	-	deoxyguanosine triphosphate
	dTTP	-	thymidine triphosphate
	UTP	-	uridine triphosphate
	NTP	-	nucleoside triphosphate
5	nmole (nM)	-	nanomole
	pmole (pM)	-	picomole
	mmole (mM)	-	millimole
	( $\mu$ M)	-	micromole
	ng	-	nanogram
10	$\mu$ g	-	microgram
	bis	-	bisacrylamide (N, N'-methylenebis-acrylamide)
	5'	-	the 5' position in the pentose
	3'	-	the 3' position in the pentose

15

EXAMPLE 1Preparation of Target DNA

A 889 basepair region of the multidrug resistance gene (MDR-1) (Figure 4, SEQ ID NO:1) was selected as a target DNA for the system. The MDR-1 gene is available from the American Type Culture Collection, ATCC No. 65704. The target DNA was prepared by the standard polymerase chain reaction with

Primer A (SEQ ID. NO:2) 5'-AGGTTAGTACCAAAGAGGCTCTGG-3' and Primer B (SEQ ID NO:3) 5'-ACTAACAGAACATCCTCAAAGCTC-3' based on the known sequence of the gene. The PCR reaction mixture comprised 1mM Tris HCl (pH 8.4), 5 mM KCl, 1.2 mM MgCl<sub>2</sub>, 0.8 mM of each dNTP, 1  $\mu$ M of Primer A, 1  $\mu$ M of Primer B, 1 ng of template DNA, 2.5 units of Amplitaq™ DNA polymerase (Perkin Elmer Cetus Corporation, Norwalk, Connecticut). The reaction mixture was heated at 94°C for 6 min., and then put through the following cycle 30 times: 94°C for 1 min, 65°C for 45 sec., and 72°C for 3 min. The final polymerization was done at 72°C for 10 min.

20  $\mu$ g of DNA was digested with 40 units of RsaI restriction endonuclease at 37°C for 2 hours under the

-25-

conditions recommended for the enzyme. An aliquot was run on an agarose gel to confirm that the DNA was completely digested. DNA was then extracted sequentially with equal volumes of phenol, phenol-chloroform (1:1) and chloroform, and then precipitated with two volumes of ethanol. The DNA pellet was suspended in deionized water and the concentration determined by measuring the optical density at 260 nm.

10

EXAMPLE 2Preparation of Oligonucleotides

Deoxynucleotide oligomers were synthesized on Milligen/Bioscience Cyclone Plus DNA Synthesizers [Millipore Corporation, Bedford, Massachusetts] using beta-cyanoethyl phosphoramidite chemistry. All reagents for oligonucleotide synthesis were purchased from Millipore Corporation [Bedford, Massachusetts].

Oligonucleotides having the following sequences were synthesized:

20 Oligo 1 (SEQ ID NO. 4):

5' CAACATTTTC ATTTCAACAA CTCC 3'

Oligo 2 (SEQ ID NO. 5):

5' TTCTTTCTTA TCTTTCAGTG CTTGTCCAGA 3'

Oligo 3 (SEQ ID NO. 6):

25 5' GGAGTTGTTG AAATGAAAAT GTTGTC 3'

After the specified sequence had been assembled, a 60 minute room temperature treatment with ammonium hydroxide was used to cleave the oligonucleotide from the support. The oligonucleotide was incubated with ammonium hydroxide at 55°C overnight treatment to remove the protecting groups. Ammonium hydroxide was evaporated to dryness in a Speedvac Concentrator [Savant Instruments, Inc., Farmingdale, New York]. The oligonucleotide was suspended in deionized water and extracted three times with an equal volume of water-saturated N-butanol. Any traces of N-butanol left were removed by evaporation in a Speedvac

Concentrator. The concentration of oligonucleotide was determined by measuring optical density at 260 nm in a spectrophotometer.

5

### EXAMPLE 3

#### Phosphorylation of oligonucleotides

Each oligonucleotide was phosphorylated at the 5' end with ATP and T4 polynucleotide kinase. The reaction mixture (100  $\mu$ l) contained 2 nmoles of each oligonucleotide  
10 50 mM Tris HCl pH 7.6, 10 mM  $MgCl_2$ , 5 mM DTT, 0.1 mM spermidine hydrochloride, 0.1 mM EDTA, 1 mM ATP and 50 units of T4 polynucleotide kinase (GIBCO BRL, Gaithersburg, Maryland). After 1 hour at 37°C, the enzyme was inactivated by heating at 65°C for 10 minutes.

15

### EXAMPLE 4

#### $^{32}P$ Labeling of oligonucleotides

Oligonucleotides (20 pmoles) were labeled with  $^{32}P$  at their 5' end in 60  $\mu$ l of 50 mM Tris HCl pH 7.6, 10 mM  
20  $MgCl_2$ , 5 mM DTT, 0.1 mM spermidine hydrochloride, 0.1 mM EDTA and 200  $\mu$ Ci of [ $\gamma$ - $^{32}P$ ] ATP (3000 Ci/mmol = 67 pmoles of ATP; NEN Research Products Div. of Dupont, Boston, Massachusetts). The reaction was started by adding 20 units of T4 polynucleotide kinase (GIBCO BRL, Gaithersburg,  
25 Maryland) and incubated at 37°C for 1 hour. T4 polynucleotide kinase was heat inactivated at 65°C for 10 minutes.

### EXAMPLE 5

#### Amplification of DNA

Oligonucleotides 1, 2 and 3 at a final concentration of 0.2  $\mu$ M were incubated in the presence or absence of target DNA (0.5 fmole =  $3 \times 10^8$  molecules) in 20  $\mu$ l of 25 mM Tris HCl pH 8.0, 10 mM KCl, 2 mM  $MgCl_2$ , 10 mM DTT, 2 mM  $NAD^+$  and  
35 50  $\mu$ M of dATP, dGTP, dCTP and dTTP. The stock solution of

-27-

dNTP's was maintained at -20°C.

Three different experiments were performed. In each case, only one oligonucleotide was labeled. 15 units of Taq ligase (New England Biolabs, Beverly, Massachusetts) and 1 unit of Amplitaq™ DNA Polymerase (Perkin-Elmer Corporation, Norwalk, Connecticut) were added and the mixture was overlaid with a drop of mineral oil. Reactions were incubated in a single reaction medium in an Ericomp™ Thermal Cycler (Ericomp Incorporation, San Diego, California) at 94°C for 6 minutes. The reaction mixture was incubated for 1 minute at 94°C, and 4 minutes at 65°C, with this cycle being repeated 30 times.

The product formation was followed independently using each <sup>32</sup>P-labeled oligonucleotide. The reaction was stopped by adding 13 µl of stop solution (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol FF). Samples were stored at -20°C until analyzed by electrophoresis.

20

#### EXAMPLE 6

##### Separation of the amplification products

The products of the amplification reaction were separated on an 8% polyacrylamide gel (acrylamide:bis; 19:1) containing 8M urea in 100 mM Tris Borate pH 8.3, 2 mM EDTA. A BRL sequencing gel apparatus model S2 (BRL, Gaithersburg, Maryland) was used to run the gel.

Samples (4 µl) were denatured by boiling before loading on the gel. Electrophoresis was performed at a constant 60 watts for 2 hours. The gel was dried and exposed to a Phospho Screen™ (Molecular Dynamics, Sunnyvale, California) and analyzed by a Phosphor Imager™ (Molecular Dynamics, Sunnyvale, California).

Figure 2 is a printout from a Phosphor Imager scan of the samples amplified by the method described in Example 5. In Lane 1 the reaction mixture contained labeled Oligo 1 and unlabeled Oligo 2 and 3. In Lane 2 the reaction

mixture was the same as in Lane 1 with the addition of target DNA. The amplified DNA band is indicated with an arrow. In Lane 3 the reaction contained labeled Oligo 2 and unlabeled Oligo 1 and 3. In Lane 4 the reaction mixture was the same as for Lane 3 with the addition of target DNA. In Lane 5 the reaction mixture contained unlabeled Oligo 1 and 2 and labeled Oligo 3. In Lane 6, the reaction mixture was the same as in Lane 5 with the addition of target DNA. It can be seen that amplification does not occur in the absence of the target DNA and that amplification can be detected by labeling any of the oligonucleotides.

#### EXAMPLE 7

##### Embodiment 2

Deoxynucleotides are synthesized on Milligen/Biosearch Cyclone Plus™ DNA synthesizers (Millipore Corporation, Bedford Massachusetts) using beta-cyanoethyl phosphoramidite chemistry as described in Example 2. The synthesis of oligonucleotides 1 and 3 was previously described in Example 2.

Oligonucleotides having the following sequences are synthesized:

Oligo 4 (SEQ ID NO:7)

5' GTTCGGAAGT TTTCTATTGC TTCAGTAGCG 3'

Oligo 5 (SEQ ID NO:8)

5' CTACTGAAGC AATAGAAAAC TTCCGAAC 3'

The oligonucleotides are either phosphorylated at the 5' end with ATP and T4 polynucleotide kinase as described in Example 3 or labeled with <sup>32</sup>P at their 5' end as described in Example 4.

The target DNA is prepared as described in Example 1.

Phosphorylated oligonucleotides at a final concentration of 0.2 μM are incubated in the presence of target DNA (0.5 fmole = 3 x 10<sup>8</sup> molecules) in 20 μl of 25 mM Tris HCl pH 8.0, 10 mM KCl, 2 mM MgCl<sub>2</sub>, 10 mM DTT, 2 mM NAD<sup>+</sup> and 50 μM

of dATP, dCTP, dGTP and dTTP. The stock solution of dNTP's are maintained at -20°C.

15 units of Taq ligase (New England Biolabs, Beverly, Massachusetts) and 1 unit of Amplitaq™ DNA polymerase (Perkin-Elmer Corporation, Norwalk, Connecticut) are added and the mixture is overlaid with a drop of mineral oil. Reactions are incubated in a single reaction medium in an Ericomp Thermal Cycler™ (Ericomp Incorporation, San Diego, California) at 94°C for 6 minutes. Then the reaction mixture is incubated for 1 minute at 94°C, and 4 minutes at 65°C, with this cycle being repeated 30 times.

The reaction is stopped by adding 13 µl of stop solution (95% v/v formamide, 20 mM EDTA, 0.05% w/v bromophenol blue, 0.05% w/v xylene cyanol FF). Samples are stored at -20°C until analyzed by electrophoresis.

The products of the amplification reaction are separated as described in Example 6.

#### EXAMPLE 8

20 This example shows the Figure 12 embodiment of the present invention which uses three primers, with a gap between the first and second primers.

Deoxynucleotides are synthesized on Milligen/Bioscience Cyclone Plus™ DNA synthesizers (Millipore Corporation, Bedford Massachusetts) using beta-cyanoethyl phosphoramidite chemistry as described in Example 2. Oligonucleotides having the following sequences are synthesized:

30 Oligo 5 (second primer) (SEQ ID NO:9):  
5' CGCCAGGGTT TTCCAGTCA CGAC 3'

Oligo 6 (first primer) (SEQ ID NO:10):  
5' CGTAATCATG GTCATAGCTG TTCCTG-NH<sub>2</sub> 3'

35 Oligo 7 (third primer) (SEQ ID NO:11):

5' GGAAACAGCT ATGACCATGA TTACGA 3'

M13mp18 phage single and double stranded DNA was obtained from New England Biolabs, Beverly, MA and used as a target in this example. Its sequence is well known, and the relevant portion from nucleotides 6201 to 6340 is as follows (SEQ ID NO:12):

6201 CACACAGGAA ACAGCTATGA CCATGATTAC GAATTCGAGC TCGGTACCCG  
10 6251 GGGATCCTCT AGAGTCGACC TGCAGGCATG CAAGCTTGGC ACTGGCCGTC  
6301 GTTTTACAAC GTCGTGACTG GGAAAACCCT GCGGTTACCC

Oligo 5 is complementary to nucleotides 6311-6334; oligo 6 is complementary to nucleotides 6205-6231. Oligos 5 and 7 at a final concentration of 0.25 $\mu$ M, and phosphorylated oligo 6 at a final concentration of 0.5 $\mu$ M were incubated in the presence of M13mp18 double stranded DNA (present at 2.5 x 10<sup>-13</sup> M) in 20 $\mu$ l of 50 mM Tris HCl pH 8.0, 10 mM DTT, 2 mM NAD, 10 mM KCl, 4 mM MgCl<sub>2</sub>, 20 $\mu$ M dATP, dGTP, dTTP and 5 $\mu$ M dCTP. Three different sets of assays were set up. In each case, only one 5'-<sup>32</sup>P labelled oligonucleotide was added. Thus, in the first case, only oligo 5 was labelled. In the second case, only oligo 6 was labelled. In the third case, only oligo 7 was labelled. Further, for each assay, a negative control was run using the same reagents except that target DNA was absent. Five units of AmpliTaq Stoffel fragment and 30 units of Taq ligase were added. Reaction tubes were incubated in GeneAmp<sup>TM</sup> PCR system 9600 thermal cycler (Perkin Elmer Cetus) at 94°C for 2 minutes (1 cycle) and then 94°C for 1 minute and 55°C for 2.5 minutes (30 cycles).

The reaction was stopped by adding stop solution (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol FF). The products of the amplification reaction were analyzed on an 8% polyacrylamide denaturing gel. The results are shown in Figure 5, which is a printout from a



were analyzed on an 8% polyacrylamide denaturing gel. The results are shown in Figure 5, which is a printout from a Phosphor Imager scan of the samples amplified in this example. In lane 1 the reaction mixture contained <sup>32</sup>P-labeled oligo 5 and unlabelled oligo 6 and 7. In lane 2 the reaction mixture was the same as in lane 1 with the addition of target DNA. The amplified DNA band is indicated with an arrow. In lane 3 the reaction mixture contained <sup>32</sup>P-labeled oligo 6 and unlabelled oligo 5 and 7. In lane 4 the reaction mixture was the same as in lane 3 with the addition of target DNA. In lane 5 the reaction mixture contained <sup>32</sup>P-labeled oligo 7 and unlabelled oligo 5 and 6. In lane 6 the reaction mixture was the same as in lane 5 with the addition of target DNA. It can be seen that the amplification does not occur in the absence of the target DNA and that amplification product can be detected by labeling any one of the three oligonucleotides.

#### EXAMPLE 9

This example shows the Figure 3 embodiment of the present invention which uses four primers, two of which are extended.

Deoxynucleotides are synthesized on Milligen/Bioscience Cyclone Plus™ DNA synthesizers (Millipore Corporation, Bedford Massachusetts) using beta-cyanoethyl phosphoramidite chemistry as described in Example 2. The synthesis of oligonucleotides 5, 6 and 7 was previously described in Example 8. An oligonucleotide having the following sequence is synthesized:

Oligo 8 (SD6) (SEQ ID NO:13):  
5' CGTGACTGGG AAAACCCTGG CGTT-Cordycepin 3'

Oligos 5 and 7 (the second and third primers, respectively) at a final concentration of 0.025μM and phosphorylated oligos 6 and 8 (first and fourth primers,

respectively) at a final concentration of 0.05 $\mu$ M were incubated in presence of M13mp18 phage double stranded DNA (2.5 x 10<sup>-13</sup> M) in 20 $\mu$ l of 50 mM TrisCl pH 8.0, 10 mM DTT, 2 mM NAD, 10 mM KCl, 4 mM MgCl<sub>2</sub>, 20 $\mu$ M dATP, dGTP, dTTP and

5 5 $\mu$ M dCTP. Four different sets of assays were set up. In each case, only one 5'-<sup>32</sup>P labelled oligonucleotide was added. Further, for each assay, a negative control was run using the same reagents without target DNA. Five units of AmliTaq stoffel fragment and 30 units of Taq ligase were  
10 added. Reaction tubes were incubated in GeneAmp™ PCR system 9600 thermal cycler (Perkin Elmer Cetus) at 94°C for 2 minute (1 cycle) and then 94°C for 1 minute and 55 °C for 2.5 minutes (30 cycles).

The reaction was stopped by adding stop solution as in  
15 Example 8. The products of the amplification reaction were analyzed on an 8% polyacrylamide denaturing gel. The results are shown in Figure 6, which is a printout from a Phosphor Imager scan of the samples amplified in this example. In lane 1 the reaction mixture contained <sup>32</sup>P-  
20 labeled oligo 5 and unlabelled oligo 6, 7 and 8. In lane 2 the reaction mixture was the same as in lane 1 with the addition of target DNA. The amplified DNA band is indicated with an arrow. In lane 3 the reaction mixture contained <sup>32</sup>P- labeled oligo 6 and unlabelled oligo 5, 7 and  
25 8. In lane 4 the reaction mixture was the same as in lane 3 with the addition of target DNA. In lane 5 the reaction mixture contained <sup>32</sup>P- labeled oligo 7 and unlabelled oligo 5, 6 and 8. In lane 6 the reaction mixture was the same as in lane 5 with the addition of target DNA. In lane 7 the  
30 reaction mixture contained <sup>32</sup>P- labeled oligo 8 and unlabelled oligo 5, 6 and 7. In lane 8 the reaction mixture was the same as in lane 7 with the addition of target DNA. It can be seen that the amplification does not occur in the absence of the target DNA and that  
35 amplification product can be detected by labeling any one of the four oligonucleotides.

EXAMPLE 10

This example shows that increasing the salt concentration and decreasing the nucleotide concentration will decrease the strand displacement activity by DNA polymerase and promote ligation by DNA ligase. Extension of a 5'-<sup>32</sup>P end labelled primer (oligo 5 from Example 8) annealed to M13mp18 single stranded DNA was monitored in the presence of another primer (oligo 6 from Example 8) which annealed 79 nucleotides down stream of oligo 5. The extension of blocking primer (oligo 6) by DNA polymerase was prevented by incorporating a NH<sub>2</sub>- group at the 3' end.

Under the assay conditions, oligo 5 was extended by DNA polymerase until it reached the 5' end of oligo 6. The extended products accumulated for some time and then the extension continued beyond the blocking primer (oligo 6). When DNA ligase was present in the assay the extended products at the 5' end of oligo 6 accumulated long enough to be ligated to oligo 5.

A. Assay conditions for strand displacement by DNA polymerase

5'-<sup>32</sup>P end labelled primer (oligo 5) (15nM) and blocking primer (oligo 6) (300nM) were simultaneously annealed to M13mp18 phage single stranded DNA (26nM). Annealing was performed in 10mM TrisCl pH 7.5, 10mM mgCl<sub>2</sub> and 50 mM NaCl, by heating at 95°C for 3 minutes followed by slow cooling to room temperature.

Strand displacement by AmpliTaq DNA polymerase was assayed by diluting the primer template complex ten fold in OCR buffer (50mM Tris HCl pH 8.0, 10mM DTT, 2mM NAD), 100mM KCl, 2mM MgCl<sub>2</sub>, 25 units/ml of AmpliTaq DNA polymerase and appropriate concentrations of deoxynucleotide triphosphates as described below. Assays using AmpliTaq DNA polymerase Stoffel fragment were performed under same conditions

except 10mM KCl and 50 units/ml of enzyme. The reaction was incubated at 55°C and aliquots were taken after 30 seconds, 1 and 2 minutes. Stop solution was added and samples were analyzed on 8% polyacrylamide denaturing gel.

5

B. Assay conditions for strand displacement by DNA  
polymerase in presence of DNA ligase

The assay were performed as in part A above except that the blocking primer was phosphorylated at the 5' end and  
10 1500 units/ml of Taq ligase (New England Biolabs) were also added. The results of both assays A and B are shown in Figures 7-10.

Fig. 7 shows the strand displacement by AmpliTaq DNA  
15 polymerase in presence of 100 mM KCl. The lanes are as follows:

	Lanes A1-A3:	20 $\mu$ M all four dNTP's.
	Lanes B1-B3:	20 $\mu$ M dA, dG, dT and 4 $\mu$ M dC
	Lanes C1-C3:	20 $\mu$ M dA, dG, dT and 2 $\mu$ M dC
20	Lanes D1-D3:	20 $\mu$ M dA, dG, dT and 1 $\mu$ M dC

Lanes A, C, G, T display the dideoxy sequencing pattern from the oligo 5 primer and M13mp18 phage DNA. The arrow points to the position where the 5' end of blocking primer (oligo 6) binds. Lanes 1, 2, 3 are 30 seconds, 1 minute  
25 and 2 minute time points, respectively.

Fig. 8 shows the strand displacement by AmpliTaq Stoffel fragment DNA polymerase in presence of 10 mM KCl. The lanes are as follows:

30	Lanes A1-A3:	20 $\mu$ M all four dNTP's
	Lanes B1-B3:	20 $\mu$ M dA, dG, dT and 10 $\mu$ M dC
	Lanes C1-C3:	20 $\mu$ M dA, dG, dT and 5 $\mu$ M dC

Lanes A, C, G, T display the dideoxy sequencing pattern from the oligo 5 primer and M13mp18 phage DNA. The arrow  
35 points to the position where th 5' end of blocking primer (oligo 6) binds. Lanes 1, 2, 3 are 30 seconds, 1 minute

and 2 minute time points, respectively.

Fig. 9 shows the strand displacement by AmpliTaq DNA polymerase in presence of 100 mM KCl and Taq ligase. The lanes are as follows:

Lanes A1-A3; B1-B3: 20  $\mu$ M all four dNTP's  
Lanes C1-C3; D1-D3: 20  $\mu$ M dA, dG, dT and 4  $\mu$ M dC  
Lanes E1-E3; F1-F3: 20  $\mu$ M dA, dG, dT and 2  $\mu$ M dC  
Lanes B1-B3, D1-D3 and F1-F3 had no ligase

Lanes A, C, G, T display the dideoxy sequencing pattern from the oligo 5 primer and M13mp18 phage DNA. The arrow points to the position of the product formed by the ligation of extended primer (oligo 5) and oligo 6. Lanes 1, 2, 3 are 30 seconds, 1 minute and 2 minute time points, respectively.

Fig. 10 shows the strand displacement by AmpliTaq Stoffel fragment DNA polymerase in presence of 10 mM KCl and Taq ligase. The lanes are as follows:

Lanes A1-A3; B1-B3: 20  $\mu$ M all four dNTP's  
Lanes C1-C3; D1-D3: 20  $\mu$ M dA, dG, dT and 10  $\mu$ M dC  
Lanes B1-B3 and D1-D3 had no ligase

Lanes A, C, G, T display the dideoxy sequencing pattern from the oligo 5 primer and M13mp18 phage DNA. The arrow points to the position of the product formed by the ligation of extended primer (oligo 5) and oligo 6. Lanes 1, 2, 3 are 30 seconds, 1 minute and 2 minute time points, respectively.

It is clear from figures 7-10 that using high salt and decreasing the concentration of the nucleotide at the 5' end of oligo 6 (which in this particular example is dCTP), oligo 5 was extended by DNA polymerase until it reached the 5' end of oligo 6. The extended products accumulated for long enough time to be ligated to oligo 6 by DNA ligase. AmpliTaq polymerase is about ten times more processive than Stoffel fragment. Therefore it requires higher salt

concentration and lower dCTP concentration to achieve a similar degree of processivity as compared to Stoffel fragment.

5

EXAMPLE 11

This example shows the Figure 1 embodiment of the present invention which uses three primers and no gap.

Deoxynucleotides are synthesized on Milligen/Biosearch Cyclone Plus™ DNA synthesizers (Millipore Corporation, Bedford Massachusetts) using beta-cyanoethyl  
10 phosphoramidite chemistry as described in Example 2. The synthesis of oligonucleotide 3 was previously described in Example 2. Oligonucleotide having the following sequences are synthesized:

15

Oligo 9 (SEQ ID NO:14)

5' AACATTTTCA TTTCAACAAC TCCTGC-Phosphate 3'

Oligo 10 (SEQ ID NO:15)

20 5' TTTCTTATCT TTCAGTGCTT GTCCAGA- araC 3'

Oligonucleotides 3 and 10 at a final concentration of 0.025μM and oligo 9 phosphorylated at the 5' end at a final concentration of 0.05μM were incubated in the presence of  
25 target DNA (5x10<sup>-12</sup>M, RsaI digested MDR-1 DNA) in 20μl of 50mM Tris HCl pH 8.0, 10 mM DTT, 2mM NAD, 10 mM KCl, 4mM MgCl<sub>2</sub>, 20μM of dATP, dCTP, dGTP, dTTP. Three different sets of assays were set up. In each case, only one 5' -<sup>32</sup>P labelled oligonucleotide was added. Thus, in the first  
30 case, only oligo 9 was labelled. In the second case only oligo 10 was labelled. In the third case, only oligo 3 was labelled. Further, for each assay, a negative control was run using the same reagents except that target DNA was absent. Five units of AmliTaq Stoffel fragment and 30  
35 units of Taq ligase were added. Reaction tubes were incubated in GeneAmp™ PCR system 9600 thermal cycler

-37-

(Perkin Elmer Cetus) at 94°C for 2 minutes (1 cycle) and then 94°C for 1 minute and 55°C for 2.5 minutes (30 cycles).

5 The reaction was stopped by adding stop solution as in example 5. The products of the amplification reaction were analyzed on an 8% polyacrylamide denaturing gel. The results are shown in figure 11, which is a printout from a Phosphor Imager scan of the samples amplified in this example. In lane 1 the reaction mixture contained <sup>32</sup>P-  
10 labeled oligo 9 and unlabelled oligo 3 and 10. In lane 2 the reaction mixture was the same as in lane 1 with the addition of target DNA. The amplified DNA band is indicated with an arrow. In lane 3 the reaction mixture contained <sup>32</sup>P- labeled oligo 10 and unlabelled oligo 3 and  
15 9. In lane 4 the reaction mixture was the same as in lane 3 with the addition of target DNA. In lane 5 the reaction mixture contained <sup>32</sup>P- labeled oligo 3 and unlabelled oligo 9 and 10. In lane 6 the reaction mixture was the same as in lane 5 with the addition of target DNA. It can be seen  
20 that the amplification does not occur in the absence of the target DNA and that amplification product can be detected by labeling any one of the three oligonucleotides. AraC at the 3' end of oligo 10 does get ligated to the 5' end of oligo 9.

25

Although only preferred embodiments of the invention are specifically illustrated and described above, it will be appreciated that many modifications and variations of the present invention are possible in light of the above  
30 teachings and within the purview of the appended claims without departing from the spirit and intended scope of the invention.

SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: BHATNAGAR, SATISH K.  
GEORGE JR., ALBERT J.
- (ii) TITLE OF INVENTION: AMPLIFICATION OF NUCLEIC  
ACID SEQUENCES
- (iii) NUMBER OF SEQUENCES: 15
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: ONCOR, INC.
  - (B) STREET: 209 PERRY PARKWAY
  - (C) CITY: GAITHERSBURG
  - (D) STATE: MARYLAND
  - (E) COUNTRY: USA
  - (F) ZIP: 20877
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: DISKETTE-3.50 INCH, 1.44 Mb  
STORAGE
  - (B) COMPUTER: APPLE MACINTOSH LC III
  - (C) OPERATING SYSTEM: MACINTOSH
  - (D) SOFTWARE: WORD PERFECT 2.1
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE: 16-DEC-1993
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: 08/010,433
  - (B) FILING DATE: 27-JAN-1993
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: KARTA, GLENN E.
  - (B) REGISTRATION NUMBER: 30,649
  - (C) REFERENCE/DOCKET NUMBER: PA-0012 CIP
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 301-963-3500
  - (B) TELEFAX: 301-926-6129
  - (C) TELEX:

## (2) INFORMATION FOR SEQ ID NO. 1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 2726 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear



## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GATTGAGAAA	GCTGTCAAGG	AAGCCAATGC	CTATGACTTT	ATCATGAAAC	50
TGCCTCATAA	ATTTGACACC	CTGGTTGGAG	AGAGAGGGGC	CCAGTTGAGT	100
GGTGGGCAGA	AGCAGAGGAT	CGCCATTGCA	CGTGCCCTGG	TTCGCAACCC	150
CAAGATCCTC	CTGCTGGATG	AGGCCACGTC	AGCCTTGGAC	ACAGAAAGCG	200
AAGCAGTGGT	TCAGGTGGCT	CTGGATAAGG	CCAGAAAAGG	TCGGACCACC	250
ATTGTGATAG	CTCATCGTTT	GTCTACAGTT	CGTAATGCTG	ACGTCATCGC	300
TGGTTTCGAT	GATGGAGTCA	TTGTGGAGAA	AGGAAATCAT	GATGAACTCA	350
TGAAAGAGAA	AGGCATTTAC	TTCAAACCTG	TCACAATGCA	GACAGCAGGA	400
AATGAAGTTG	AATTAGAAAA	TGCAGCTGAT	GAATCCAAAA	GTGAAATTGA	450
TGCCTTGGAA	ATGTCCTCAA	ATGATTCAAG	ATCCAGTCTA	ATAAGAAAAA	500
GATCAACTCG	TAGGAGTGTC	CGTGGATCAC	AAGCCCAAGA	CAGAAAGCTT	550
AGTACCAAAG	AGGCTCTGGA	TGAAAGTATA	CCTCCAGTTT	CCTTTTGGAG	600
GATTATGAAG	CTAAATTTAA	CTGAATGGCC	TTATTTTGTT	GTTGGTGTAT	650
TTTGTGCCAT	TATAAATGGA	GGCCTGCAAC	CAGCATTGTC	AATAATATTT	700
TCAAAGATTA	TAGGGGTTTT	TACAAGAATT	GATGATCCTG	AAACAAAACG	750
ACAGAATAGT	AACCTGTTTT	CACATATTGT	TCTAGCCCTT	GGAATTATTT	800
CTTTTATTAC	ATTTTTCCTT	CAGGGTTTCA	CATTTGGCAA	AGCTGGAGAG	850
ATCCTCACCA	AGCGGCTCCG	ATACATGGTT	TTCCGATCCA	TGCTCAGACA	900
GGATGTGAGT	TGGTTTGATG	ACCTTAAAAA	CACCACTGGA	GCATTGACTA	950
CCAGGCTCGC	CAATGATGCT	GCTCAAGTTA	AAGGGGCTAT	AGGTTCCAGG	1000
CTTGCTGTAA	TTACCCAGAA	TATAGCAAAT	CTTGGGACAG	GAATAATTAT	1050
ATCCTTCATC	TATGGTTGGC	AACTAACACT	GTTACTCTTA	GCAATTGTAC	1100
CCACTATTGC	AATAGCAGGA	GTTGTTGAAA	TGAAAATGTT	GTCTGGACAA	1150
GCAC TGAAAG	ATAAGAAAAG	ACTAGAAGGT	GCTGGGAAGA	TCGCTACTGA	1200
AGCAATAGAA	AACTTCCGAA	CCGTTGTTTC	TTTGACTCAG	GAGCAGAAGT	1250
TTGAACATAT	GTATGCTCAG	AGTTTGCAGG	TACCATACAG	AAACTCTTTG	1300
AGGAAAGCAC	ACATCTTTGG	AATTACATTT	TCCTTCACCC	AGGCAATGAT	1350
GTATTTTTC	TATGCTGGAT	GTTTCCGGTT	TGGAGCCTAC	TTGGTGGCAC	1400
ATAAACTCAT	GAGCTTTGAG	GATGTTCTGT	TAGTATTTTC	AGCTGTTGTC	1450
TTTGGTGCCA	TGGCCGTGGG	GCAAGTCAGT	TCATTTGCTC	CTGACTATGC	1500
CAAAGCCAAA	ATATCAGCAG	CCCACATCAT	CATGATCATT	GAAAAAACCC	1550
CTTTGATTGA	CAGCTACAGC	ACGGAAGGCC	TAATGCCGAA	CACATTGGAA	1600
GGAAATGTCA	CATTTGGTGA	AGTTGTATTC	AACTATCCCA	CCCAGCCGGA	1650
CATCCCAGTG	CTTCAGGGAC	TGAGCCTGGA	GGTGAAGAAG	GGCCAGACGC	1700
TGGCTCTGGT	GGGCAGCAGT	GGCTGTGGGA	AGAGCACAGT	GGTCCAGCTC	1750
CTGGAGCGGT	TCTACGACCC	CTTGGCAGGG	AAAGTGCTGC	TTGATGGCAA	1800
AGAAATAAAG	CGACTGAATG	TTCAGTGGCT	CCGAGCACAC	CTGGGCATCG	1850
TGTCCCAGGA	GCCCATCCTG	TTTGACTGCA	GCATTGCTGA	GAACATTGCC	1900
TATGGAGACA	ACAGCCGGGT	GGTGTCACAG	GAAGAGATCG	TGAGGGCAGC	1950
AAAGGAGGCC	AACATACATG	CCTTCATCGA	GTCACCTGCT	AATAAATATA	2000
GCACTAAAGT	AGGAGACAAA	GGAAC TCAGC	TCTCTGGTGG	CCAGAAACAA	2050
CGCATTGCCA	TAGCTCGTGC	CCTTGTTAGA	CAGCCTCATA	TTTTGCTTTT	2100
GGATGAAGCC	ACGTCAGCTC	TGGATACAGA	AAGTGAAAAG	GTTGTCCAAG	2150
AAGCCCTGGA	CAAAGCCAGA	GAAGGCCGCA	CCTGCATTGT	GATTGCTCAC	2200
CGCCTGTCCA	CCATCCAGAA	TGCAGACTTA	ATAGTGGTGT	TTCAGAATGG	2250
CAGAGTCAAG	GAGCATGGCA	CGCATCAGCA	GCTGCTGGCA	CAGAAAGGCA	2300
TCTATTTTTC	AATGGTCAGT	GTCCAGGCTG	GAACAAAGCG	CCAGTGAAC T	2350
CTGACTGTAT	GAGATGTTAA	ATACTTTTTA	ATATTTGTTT	AGATATGACA	2400
TTTATTCAAA	GTTAAAAGCA	AACACTTACA	GAATTATGAA	GAGGTATCTG	2450
TTTAAACATTT	CCTCAGTCAA	GTTCAGAGTC	TTCAGAGACT	TCGTAATTA	2500
AGGAACAGAG	TGAGAGACAT	CATCAAGTGG	AGAGAAATCA	TAGTTTAAAC	2550
TGCATTATAA	ATTTTATAAC	AGAATTAAAG	TAGATTTTAA	AAGATAAAAT	2600

-40-

GTGTAATTTT GTTTATATTT TCCCATTTGG ACTGTAAGTG ACTGCCTTGC 2650  
TAAAAGATTA TAGAAGTAGC AAAAAGTATT GAAATGTTTG CATAAAGTGT 2700  
CTATAATAAA ACTAAACTTT CATGTG 2726

## (2) INFORMATION FOR SEQ ID NO. 2:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:  
AGGTTAGTAC CAAAGAGGCT CTGG

24

## (2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ACTAACAGAA CATCCTCAAA GCTC

24

## (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CAACATTTTC ATTTCAACAA CTCC

24

## (2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 30 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TTCTTTCTTA TCTTTCAGTG CTTGTCCAGA

30

## (2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:

-41-

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GGAGTTGTTG AAATGAAAAT GTTGTC

26

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GTTCGGAAGT TTTCTATTGC TTCAGTAGCG

30

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CTACTGAAGC AATAGAAAAC TTCCGAAC

28

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CGCCAGGGTT TTCCCAGTCA CGAC

24

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CGTAATCATG GTCATAGCTG TTTCCTG

27

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GGAAACAGCT ATGACCATGA TTACGA

26

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 140 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CACACAGGAA	ACAGCTATGA	CCATGATTAC	GAATTCGAGC	TCGGTACCCG	50
GGGATCCTCT	AGAGTCGACC	TGCAGGCATG	CAAGCTTGGC	ACTGGCCGTC	100
GTTTTACAAC	GTCGTGACTG	GGAAACCCT	GGCGTTACCC		140

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CGTGACTGGG AAAACCCTGG CGTT

24

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

AACATTTTCA TTTCAACAAC TCCTGC

26

-43-

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 27 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TTTCTTATCT TTCAGTGCTT GTCCAGA

27

WHAT IS CLAIMED IS:

1. A process for amplifying enzymatically a target nucleic acid sequence contained in a nucleic acid or a mixture of nucleic acids, comprising the steps of:
  - a) selecting the target nucleic acid sequence;
  - b) providing primers, said primers comprising a first primer which is substantially complementary to a first segment at a first end of the target nucleic acid sequence and a second primer which is substantially complementary to a second segment at a second end of the target nucleic acid sequence and whose 3' end is adjacent to the 5' end of the first primer and a third primer which is similar to the first end of the target nucleic acid sequence and which is substantially complementary to at least a portion of said first primer;
  - c) providing at least four different nucleotide bases;
  - d) hybridizing said first and second primers to the target nucleic acid sequence in a target dependent manner to form a primer-target complex;
  - e) ligating under conditions such that the adjacent 5' end of the first primer and the 3' end of the second primer will ligate to form a fused amplification product substantially complementary to said target nucleic acid sequence;
  - f) dissociating said fused amplification product from said target nucleic acid sequence;
  - g) hybridizing said third primer to said fused amplification product;
  - h) extending said third primer in the presence of the nucleotide bases under conditions such that an extended amplification product is formed substantially complementary to said fused amplification product; and
  - i) optionally dissociating the extended amplification product from the fused amplification product,

to thereby amplify the target sequence.

2. The process of Claim 1, wherein the target nucleic acid is single stranded.

5

3. The process of Claim 1, wherein steps (d) through (i) are repeated at least once.

4. The process of Claim 1, wherein the target nucleic acid is DNA.

10

5. The process of Claim 1, wherein the target nucleic acid is RNA.

6. The process of Claim 1, wherein step (e) is conducted in the presence of a ligating enzyme.

15

7. The process of Claim 6, wherein the ligating enzyme is T4 DNA ligase.

20

8. The process of Claim 6, wherein the ligating enzyme is stable at 0-95°C.

9. The process of Claim 8, wherein the ligating enzyme is selected from the group consisting of Taq ligase, Pfu ligase and Ampligase.

25

10. The process of Claim 1, wherein step (h) is conducted in the presence of a polymerase.

30

11. The process of Claim 10, wherein step (h) is conducted in the presence of a polymerase selected from the group consisting of E. coli DNA polymerase I, Klenow fragment of E. coli DNA polymerase I, and T4 DNA polymerase.

35

-46-

12. The process of Claim 10, wherein step (h) is conducted in the presence of a polymerase which is stable at temperatures of 0-95°C.

5        13. The process of Claim 12, wherein the agent for polymerization is selected from the group consisting of Taq DNA polymerase and AmpliTaq Stoffel fragment DNA polymerase.

10       14. The process of Claim 1, wherein the target nucleic acid sequence contains at least one deletion or mutation that causes a genetic disease or cancer.

15       15. The process of Claim 1, wherein the target nucleic acid sequence is contained in a pathogenic organism, virus or oncogene.

20       16. The process of Claim 1, wherein one of said primers comprises two or more different oligonucleotides, one of said oligonucleotides having a sequence exactly complementary to said target nucleic acid sequence.

25       17. The process of Claim 1, wherein the target nucleic acid is double stranded nucleic acid comprising a first and second strand wherein said first and second primers are substantially complementary to said first strand and said third primer is substantially complementary to said second strand and said first and second strands are dissociated prior to step (d), and wherein at least some of the third  
30       primers hybridize to the second strand and are extended to form an extended amplification product.

35       18. The process of Claim 1, wherein each of the steps is conducted sequentially without isolation or purification of the products.



19. The process of Claim 18 wherein each of the steps is conducted in a single reaction medium.

20. The process of Claim 1, wherein the 5' end of the first primer comprises a phosphorothioate group.

21. The process of Claim 1, wherein the 3' end of the second primer comprises an arabinosyl nucleotide.

22. A process for detecting enzymatically a mutation or an allele in a target nucleic acid sequence contained in a nucleic acid or a mixture of nucleic acids, comprising the steps of:

- a) selecting the target nucleic acid sequence;
- b) providing primers, said primers comprising a first primer which is substantially complementary to a first segment at a first end of the target nucleic acid sequence and a second primer which is substantially complementary to a second segment at a second end of the target nucleic acid sequence and whose 3' end is adjacent to the 5' end of the first primer and a third primer which is similar to the first end of the target nucleic acid sequence and which is substantially complementary to at least a portion of said first primer, wherein one of said primers comprises two or more different oligonucleotides, one of said oligonucleotides having a sequence exactly complementary to said target nucleic acid sequence wherein each oligonucleotide is labeled with a different label;
- c) providing at least four different nucleotide bases;
- d) hybridizing said first and second primers to the target nucleic acid sequence in a target dependent manner to form a primer-target complex;
- e) ligating under conditions such that the adjacent 5' end of the first primer and the 3' end of the second primer will ligate to form a fused amplification product

substantially complementary to said target nucleic acid sequence;

f) dissociating said fused amplification product from said target nucleic acid sequence;

5 g) hybridizing said third primer to said fused amplification product;

h) extending said third primer in the presence of the nucleotide bases under conditions such that an extended amplification product is formed substantially complementary to said fused amplification product;

10 i) optionally dissociating the extended amplification product from the fused amplification product; and

j) determining which labeled primer is contained within the fused amplification product or the extended amplification product to thereby detect whether the mutation or allele is present.

23. A process for amplifying enzymatically a target nucleic acid sequence contained in a nucleic acid or a mixture of nucleic acids comprising the steps of:

a) selecting the target nucleic acid sequence;

b) providing primers, said primers comprising a first primer which is substantially complementary to a first segment at a first end of the target nucleic acid sequence and a second primer which is substantially complementary to a second segment at a second end of the target nucleic acid sequence said second segment being spaced a number of nucleotides from said first segment and a third primer which is similar to the first end of the target nucleic acid sequence and which is substantially complementary to at least a portion of said first primer;

c) providing at least four different nucleotide bases;

35 d) hybridizing said first and second primers to the target nucleic acid sequence in a target dependent manner

to form a primer-target complex;

e) extending the 3' end of the second primer in the presence of the nucleotide bases under conditions such that an extended second primer is formed wherein the 3' end of  
5 the extended second primer terminates at a base adjacent to the 5' end of the first primer;

f) ligating the ends of the first and second extended primers under conditions such that said first and said extended second primers will form a fused  
10 amplification product substantially complementary to said target nucleic acid sequence;

g) dissociating said fused amplification product from said target nucleic acid sequence;

h) hybridizing said third primer to said fused  
15 amplification product;

i) extending said third primer in the presence of the nucleotide bases under conditions such that an extended amplification product is formed substantially complementary to said fused amplification product; and

20 j) optionally dissociating the extended amplification product from the fused amplification product, to thereby amplify the target sequence.

24. The process of Claim 23, wherein steps (d) and (j)  
25 are repeated at least once.

25. The process of Claim 23, wherein the target nucleic acid is double stranded nucleic acid comprising a first and second strand wherein said first and second primers are  
30 substantially complementary to said first strand and said third primer is substantially complementary to said second strand and said first and second strands are dissociated prior to step (d), and wherein at least some of the third primers hybridize to the second strand and are extended to  
35 form an extended amplification product.

26. The process of Claim 25, further comprising a fourth primer wherein the fourth primer is substantially complementary to said second target nucleic acid strand and said fourth primer is substantially complementary to said second primer, and wherein the third primer is extended to the 3' end of the fourth primer and is ligated thereto.

27. The process of Claim 26, wherein the nucleic acid is denatured by heating.

28. The process of Claim 23, wherein the nucleic acid is DNA.

29. The process of Claim 23, wherein the nucleic acid is RNA.

30. The process of Claim 23, wherein step (f) is conducted in the presence of a ligating enzyme.

31. The process of Claim 30, wherein the ligating enzyme is T4 DNA ligase.

32. The process of Claim 30, wherein the ligating enzyme is stable at 0-95°C.

33. The process of Claim 32, wherein the ligating enzyme is selected from the group consisting of Ampligase, Taq ligase and Pfu ligase.

34. The process of Claim 23 wherein steps (e) and (i) are conducted in the presence of polymerase.

35. The process of Claim 34, wherein steps (e) and (i) are conducted in the presence of a polymerase selected from the group consisting of E. coli DNA polymerase I, Klenow fragment of E. coli DNA polymerase I and T4 DNA polymerase.

36. The process of Claim 34, wherein steps (e) and (i) are conducted in the presence of a polymerase which is stable at 0-95°C.

5

37. The process of Claim 36, wherein the polymerase is selected from the group consisting of Taq DNA polymerase and AmpliTaq Stoffel fragment DNA polymerase.

10 38. The process of Claim 23, wherein the target nucleic acid sequence contains at least one deletion or mutation that causes a genetic disease.

15 39. The process of Claim 23, wherein the target nucleic acid sequence is contained in a pathogenic organism, virus or oncogene.

20 40. The process of Claim 23, wherein one of said primers comprises two or more oligonucleotides, one of said oligonucleotides having a sequence exactly complementary to said target nucleic acid.

25 41. The process of Claim 23, wherein each of the steps is conducted sequentially without isolation or purification of the products.

42. The process of Claim 41, wherein each of the steps is conducted in a single reaction medium.

30 43. The process of Claim 23, wherein the 5' end of the first primer comprises an phosphorothioate group.

44. The process of Claim 26, wherein the 5' end of the fourth primer comprises an phosphorothioate group.

35

45. A process for detecting enzymatically a mutation or

an allele in a target nucleic acid sequence contained in a nucleic acid or a mixture of nucleic acids comprising the steps of

- a. selecting the target nucleic acid sequence;
- 5      b. providing primers, said primers comprising a first primer which is substantially complementary to a first segment at a first end of the target nucleic acid sequence and a second primer which is substantially complementary to a second segment at a second end of the target nucleic acid sequence said second segment being spaced from said first segment and a third primer which is similar to the first end of the target nucleic acid sequence and which is substantially complementary to at least a portion of said first primer wherein one of said primers comprises two or more different oligonucleotides, one of said oligonucleotides having a sequence exactly complementary to said target nucleic acid sequence wherein each oligonucleotide is labeled with a different label;
- 10      c. providing at least four different nucleotide bases;
- 20      d. hybridizing said first and second primers to the target nucleic acid sequence in a target dependent manner to form a primer-target complex;
- 25      e. extending the 3' end of the second primer in the presence of the nucleotide bases under conditions such that an extended second primer is formed wherein the 3' end of the extended second primer is adjacent to the 5' end of the first primer;
- 30      f. ligating the ends of the first and second primers under conditions such that said first and said extended second primers will form a fused amplification product complementary to said target nucleic acid sequence;
- 35      g. dissociating said fused amplification product from said target nucleic acid sequence;
- h. hybridizing said third primer to said fused amplification product;

i. extending said third primer in the presence of the nucleotide bases under conditions such that an extended amplification product is formed complementary to said fused amplification product; and

5 j. optionally dissociating the extended amplification product from the fused amplification product; and

10 k. determining which labeled primer is contained within the fused amplification product or the extended amplification product to thereby detect whether the mutation or allele is present.

46. A kit for amplifying at least one target nucleic acid sequence contained in a nucleic acid or a mixture of  
15 nucleic acids, comprising:

- a. first, second and third primers and optionally a fourth primer;
- b. a ligating enzyme;
- c. a polymerizing enzyme; and
- 20 d. at least four different nucleotides.

47. The kit of Claim 46 further comprising:

- e. a detectable marker attached to one of said  
25 primers.

48. The kit of Claim 46, further comprising:

- e. a buffer suitable for the ligation and polymerization reactions.

30 49. The process of Claim 4, wherein the DNA source is selected from the group consisting of plants, animals, insects and microorganisms.

35 50. The process of Claim 5, wherein the RNA source is selected from the group consisting of plants, animals, insects and microorganisms.

51. The process of Claim 28, wherein the DNA source is selected from the group consisting of plants, animals, insects and microorganisms.

- 5      52. The process of Claim 29, wherein the RNA source is selected from the group consisting of plants, animals, insects and microorganisms.







FIG.1

1 2 3 4 5 6

**FIG.2**






FIG.3

1921	GATTGAGAAA	GCTGTCAAGG	AAGCCAATGC	CTATGACTTT	ATCATGAAAC	TGCCTCATAA
1981	ATTTGACACC	CTGGTTGGAG	AGAGAGGGGC	CCAGTTGAGT	GGTGGGCAGA	AGCAGAGGAT
2041	CGCCATTGCA	CGTGCCCTGG	TTCGCAACCC	CAAGATCCTC	CTGCTGGATG	AGGCCACGTC
2101	AGCCTTGGAC	ACAGAAAGCG	AAGCAGTGGT	TCAGGTGGCT	CTGGATAAGG	CCAGAAAAGG
2161	TCGGACCACC	ATTGTGATAG	CTCATCGTTT	GTCTACAGTT	CGTAATGCTG	ACGTCATCGC
2221	TGGTTTCGAT	GATGGAGTCA	TTGTGGAGAA	AGGAAATCAT	GATGAACTCA	TGAAAGAGAA
2281	AGGCATTTAC	TTCAAACCTG	TCACAATGCA	GACAGCAGGA	AATGAAGTTG	AATTAGAAAA
2341	TGCAGCTGAT	GAATCCAAAA	GTGAAATTGA	TGCCCTTGAA	ATGTCTTCAA	ATGATTCAAG
2401	ATCCAGTCTA	ATAAGAAAAA	GATCAACTCG	TAGGAGTGTC	CGTGGATCAC	AAGCCCAAGA
2461	CAGAAAGCTT	AGTACCAAAG	AGGCTCTGGA	TGAAAGTATA	CCTCCAGTTT	CCTTTTGGAG
2521	GATTATGAAG	CTAAATTTAA	CTGAATGGCC	TTATTTTGT	GTTGGTGTAT	TTTGTGCCAT
2581	TATAAATGGA	GGCCTGCAAC	CAGCATTTCG	AATAATATTT	TCAAAGATTA	TAGGGGTTTT
2641	TACAAGAATT	GATGATCCTG	AAACAAAACG	ACAGAATAGT	AACTTGTTTT	CACTATTGTT
2701	TCTAGCCCTT	GGAATTATTT	CTTTTATTAC	ATTTTTCCTT	CAGGGTTTCA	CATTTGGCAA
2761	AGCTGGAGAG	ATCCTCACCA	AGCGGCTCCG	ATACATGGTT	TTCCGATCCA	TGCTCAGACA
2821	GGATGTGAGT	TGGTTTGATG	ACCCATAAAA	CACCACTGGA	GCATTGACTA	CCAGGCTCGC
2881	CAATGATGCT	GCTCAAGTTA	AAGGGGCTAT	AGGTTCCAGG	CTTGCTGTAA	TTACCCAGAA
2941	TATAGCAAA	CTTGGGACAG	GAATAATTAT	ATCCTTCATC	TATGGTTGGC	AACTAACACT
3001	GTTACTCTTA	GCAATTGTAC	CCATCATTGC	AATAGCAGGA	GTTGTTGAAA	TGAAAATGTT
3061	GTCTGGACAA	GCACTGAAAG	ATAAGAAAGA	ACTAGAAGGT	GCTGGGAAGA	TCGCTACTGA
3121	AGCAATAGAA	AACCTCCGAA	CCGTTGTTTC	TTTGACTCAG	GAGCAGAAGT	TTGAACATAT
3181	GTATGCTCAG	AGTTTGCAGG	TACCATACAG	AAACTCTTTG	AGGAAAGCAC	ACATCTTTGG
3241	AATTACATTT	TCCTTCACCC	AGGCAATGAT	GTATTTTTC	TATGCTGGAT	GTTTCCGGTT
3301	TGGAGCCTAC	TTGGTGGCAC	ATAAACTCAT	GAGCTTTGAG	GATGTTCTGT	TAGTATTTTC
3361	AGCTGTTGTC	TTTGGTGCCA	TGGCCGTGGG	GCAAGTCAGT	TCATTTGCTC	CTGACTATGC
3421	CAAAGCCAAA	ATATCAGCAG	CCCACATCAT	CATGATCATT	GAAAAAACCC	CTTTGATTGA
3481	CAGCTACAGC	ACGGAAGGCC	TAATGCCGAA	CACATTGGAA	GGAAATGTCA	CATTTGGTGA
3541	AGTTGTATT	AACTATCCCA	CCCGACCGGA	CATCCCAAGT	CTTCAGGGAC	TGAGCCTGGA
3601	GGTGAAGAAG	GGCCAGACGC	TGGCTCTGGT	GGGCAGCAGT	GGCTGTGGGA	AGAGCACAGT
3661	GGTCCAGCTC	CTGGAGCGGT	TCTACGACCC	CTTGGCAGGG	AAAGTGCTGC	TTGATGGCAA
3721	AGAAATAAAG	CGACTGAATG	TTCAGTGCT	CCGAGCACAC	CTGGGCATCG	TGTCCCAGGA
3781	GCCCATCCTG	TTTGACTGCA	GCATTGCTGA	GAACATTGCC	TATGGAGACA	ACAGCCGGGT
3841	GGTGTACACG	GAAGAGATCG	TGAGGGCAGC	AAAGGAGGCC	AACATACATG	CCTTCATCGA
3901	GTCAGTGCCT	AATAAATATA	GCACTAAAGT	AGGAGACAAA	GGAACCTCAG	TCTCTGGTGG
3961	CCAGAAACAA	CGCATTGCCA	TAGCTCGTGC	CCTTGTTAGA	CAGCCTCATA	TTTTGCTTTT
4021	GGATGAAGCC	ACGTCAGCTC	TGGATACAGA	AAGTGAAAAG	GTTGTCCAAG	AAGCCCTGGA
4081	CAAAGCCAGA	GAAGGCCGCA	CCTGCATTGT	GATTGCTCAC	CGCCTGTCCA	CCATCCAGAA
4141	TGCAGACTTA	ATAGTGGTGT	TTCAGAATGG	CAGAGTCAAG	GAGCATGGCA	CGCATCAGCA
4201	GCTGCTGGCA	CAGAAAGGCA	TCTATTTTTC	AATGGTCAGT	GTCCAGGCTG	GAACAAAGCG
4261	CCAGTGAAC	CTGACTGTAT	GAGATGTTAA	ATACTTTTTA	ATATTTGTTT	AGATATGACA
4321	TTTATTCAAA	GTTAAAAGCA	AACACTTTACA	GAATTATGAA	GAGGTATCTG	TTTAACATTT
4381	CCTCAGTCAA	GTTTCAAGTC	TTCAGAGACT	TCGTAATTAA	AGGAACAGAG	TGAGAGACAT
4441	CATCAAGTGG	AGAGAAATCA	TAGTTTAAAC	TGCATTATAA	ATTTTATAAC	AGAATTAAG
4501	TAGATTTTAA	AAGATAAAAT	GTGTAATTTT	GTTTATATTT	TCCCATTGGG	ACTGTAACCTG
4561	ACTGCCTTGC	TAAAAGATTA	TAGAAGTAGC	AAAAAGTATT	GAAATGTTTG	CATAAAGTGT
4621	CTATAATAAA	ACTAAACTTT	CATGTG			

FIG.4

5/12







FIG.5



6/12



**FIG.6**



7/12




FIG.7

8/12




FIG.8



9/12




FIG.9

10/12

A1 A2 A3 B1 B2 B3 C1 C2 C3 D1 D2 D3





FIG.10

11/12



FIG.11






FIG.12

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US94/00748

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(5) : C12Q 1/68; C12P 19/34 US CL : 435/6, 91.5 According to International Patent Classification (IPC) or to both national classification and IPC				
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6, 91.5  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MEDLINE				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
Y	US, A, 4,683,195 (MULLIS ET AL.) 28 JULY 1987, See entire document	1-52		
Y	WO, A, 90/01069 (SEGEV) 08 FEBRUARY 1990, See entire document.	1-52		
Y	ERLICH et al., "POLYMERASE CHAIN REACTION," published 1990 by COLD SPRING HARBOR LABORATORY PRESS (N.Y.), see pages 75-81.	45		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.				
<table border="0"> <tr> <td>           * Special categories of cited documents:            *A* document defining the general state of the art which is not considered to be part of particular relevance            *E* earlier document published on or after the international filing date            *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)            *O* document referring to an oral disclosure, use, exhibition or other means            *P* document published prior to the international filing date but later than the priority date claimed         </td> <td>           *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention            *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone            *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art            *A* document member of the same patent family         </td> </tr> </table>			* Special categories of cited documents: *A* document defining the general state of the art which is not considered to be part of particular relevance *E* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *A* document member of the same patent family
* Special categories of cited documents: *A* document defining the general state of the art which is not considered to be part of particular relevance *E* earlier document published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *A* document member of the same patent family			
Date of the actual completion of the international search 03 APRIL 1994		Date of mailing of the international search report APR 25 1994		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer SCOTT HOUTTEMAN <i>Jeff Warden for</i> Telephone No. (703) 308-0196		